VERAXA Biotech Acquired | Healthcare M&A Deal

VERAXA Biotech has completed the financing and related healthcare M&A steps for VERAXA Biotech, a healthcare services other business in Zurich, for $27.5 million. VERAXA Biotech develops next-generation cancer therapies, including bispecific T-cell engagers (BiTAC-TCEs) and antibody-drug conjugates (BiTAC-ADCs), to advance programs toward clinical development. The healthcare services other acquisition supports pipeline progression and initial value inflection points while preparing for a Nasdaq Capital Market listing. As part of the VERAXA Biotech acquisition and other acquisition structure, the company entered a senior secured note securities purchase agreement with an institutional investor for $27.5 million and a $50 million share purchase agreement with Lincoln Park Capital Fund, supporting the closing of its business combination with Voyager Acquisition Corp.